Form 4: Medicus Pharma CFO Exercises Options, Boosts Shareholding

Medicus Pharma's Chief Financial Officer, James P. Quinlan, exercised stock options to acquire 145,000 common shares, increasing his direct beneficial ownership to 274,147 shares.

Summary

• James P. Quinlan, Chief Financial Officer of Medicus Pharma Ltd. (MDCX), acquired a total of 145,000 common shares through the exercise of stock options on August 13, 2025.
• This includes the acquisition of 125,000 common shares at an exercise price of $0.81 per share.
• An additional 20,000 common shares were acquired at an exercise price of $2.75 per share.
• Following these transactions, Mr. Quinlan's direct beneficial ownership in Medicus Pharma Ltd. stands at 274,147 common shares.
• The options exercised were vested and exercisable as of the transaction date.
• The U.S. dollar exercise prices were derived from Canadian dollar prices ($1.16 CAD and $3.95 CAD, respectively) using a daily average exchange rate of CAD$1.4379 to $1.00 USD, reported by the Bank of Canada on December 30, 2024.

Sentiment

Score: 7

Explanation: The Chief Financial Officer's decision to exercise options and increase direct share ownership suggests a positive outlook on the company's future performance and valuation, indicating confidence from a key insider.

Positives

• Increased insider ownership by a key executive (CFO) signals confidence in the company's future prospects and alignment with shareholder interests.
• The exercise of stock options indicates a belief by management that the current share price is favorable or that future appreciation is expected.

Negatives

• The exercise of options, while increasing beneficial ownership, could potentially precede future sales, though no such sales are reported in this filing.

Future Outlook

NA

Management Comments

• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased insider ownership by a key executive can be viewed positively, signaling management's alignment with shareholder interests and confidence in the company's future.

Key Dates

Keywords

Medicus Pharma, MDCX, James P. Quinlan, CFO, insider transaction, stock option, beneficial ownership, equity acquisition, SEC Form 4